Since WA displays high a similarity with IBR mode of action, but with a more potent effect on cell death of GC-resistant MM cells, further structure-function analysis of WA-analogs may allow (pre)clinical optimization of highly effective withanolide BCR inhibitors to expand the arsenal of cancer drugs against therapy-resistant B-cell malignancies. Here, BCR is linked to cancer.